GOLD/GLI联合声明解读:肺量计界定气流阻塞与慢阻肺诊断
2026年GOLD与GLI就肺量计界定气流阻塞及慢阻肺诊断发布联合声明。声明指出固定FEV1/FVC<0.70与LLN分别服务于临床和流行病学目的,强调肺量计应用不足、质量不稳及脱离临床背景解读等问题,并结合中国证据提出筛查优化建议。
要点
- GOLD推荐症状者吸入支气管舒张剂后FEV1/FVC<0.70确认持续气流阻塞。
- GLI支持用LLN识别生理性气流阻塞,减少年龄相关误分类。
- 肺量计正常不能排除但可帮助排除慢阻肺,接近阈值者应复查或进一步评估。
核心结论
- 固定比值与LLN不应视为竞争定义,而是服务于不同临床与流行病学目标的工具。
- 肺量计应用不足、检查质量不稳定及脱离临床背景解读是当前更紧迫的全球挑战。
研究设计与样本
- 本文为对2026年GOLD与GLI联合声明的解读综述,整合中国社区与真实世界证据。
主要发现
- GOLD继续推荐吸入支气管舒张剂后FEV1/FVC<0.70确认持续气流阻塞。
- GLI支持用LLN识别生理性气流阻塞,尤其减少年龄相关误分类。
- 声明支持过渡至2022年GLI种族中立参考方程,但预计值与严重度分类需谨慎解读。
- GOLD百分比预计值阈值与ATS/ERS z-score分类均存在固有局限。
关键数值与推荐
- GOLD推荐吸入支气管舒张剂后FEV1/FVC<0.70用于有症状且相关暴露者确认持续气流阻塞。
- GLI支持用LLN识别生理性气流阻塞。
- 声明支持过渡至2022年GLI种族中立参考方程。
- 肺量计正常结果不能排除但可帮助排除慢阻肺,接近诊断阈值者应复查或进一步临床评估。
临床怎么用
- 临床应结合症状、暴露史与肺量计结果综合判断,避免机械解读。
- 接近诊断阈值者应重复肺量计检查或进一步临床评估。
- 生理损害评估需结合症状、急性加重风险、共病、影像及临床有意义结局。
局限性
- 本文为声明解读综述,非原始研究,未提供新的样本量或效应量。
- 声明未简单判定固定比值与LLN优劣,二者选择需结合临床与流行病学目的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic obstructive pulmonary disease(COPD) remains a leading cause of mortality worldwide, and spirometry is the essential objective test for identifying airflow obstruction and confirming COPD in the appropriate clinical context. In 2026, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Lung Function Initiative(GLI) published a joint statement on the use of spirometry to define airflow obstruction and diagnose COPD. This statement reframes the long-standing debate between the fixed FEV1/FVC ratio and the lower limit of normal(LLN), emphasizing that these criteria should not be viewed simply as competing definitions, but as tools serving different clinical and epidemiological purposes.GOLD continues to recommend a fixed post-bronchodilator FEV1/FVC ratio of <0.70 to confirm persistent airflow obstruction in symptomatic individuals with relevant exposures, whereas GLI supports using the LLN to identify physiological airflow obstruction across populations, particularly to mitigate age-related misclassification. The joint statement further highlights that major global challenges extend beyond threshold selection to include the underuse of spirometry, variable test quality, and the interpretation of spirometric results without sufficient clinical context. Furthermore, spirometry alone is insufficient for diagnosing COPD; however, normal spirometric findings from technically acceptable tests can help exclude COPD. Results near diagnostic thresholds warrant repeat testing or further clinical evaluation.The statement also supports transitioning to the 2022 GLI race-neutral reference equations while cautioning that predicted values and severity classifications require careful interpretation across diverse populations. Regarding severity grading, both GOLD percent-predicted thresholds and ATS/ERS z-score classifications possess inherent limitations. Consequently, physiological impairment should be evaluated alongside symptoms, exacerbation risk, comorbidities, imaging findings, and clinically meaningful outcomes.This review summarizes the main viewpoints of the GOLD-GLI joint statement, focusing on the practical differences between the fixed ratio and LLN, barriers to spirometry implementation, quality assurance, reference equations, and severity grading. In addition, we integrate recent Chinese community-based and real-world evidence, including simplified pre-bronchodilator spirometry for population screening, portable spirometry in primary care, and artificial intelligence-assisted spirometry interpretation. By combining updated international consensus with local evidence and emerging technologies, this article provides a practical reference for standardizing COPD diagnosis and optimizing screening strategies in China. 慢性阻塞性肺疾病(简称慢阻肺病)是全球主要致死性疾病之一,肺量计检查仍是识别气流阻塞和确认慢阻肺病诊断的核心客观工具。2026年,慢性阻塞性肺疾病全球倡议(GOLD)与全球肺功能倡议(GLI)就肺量计界定气流阻塞及慢阻肺病诊断发布联合声明。GOLD主张采用吸入支气管舒张剂后FEV1/FVC<0.70的固定比值,GLI则强调依据年龄、身高、性别等因素计算的正常值下限(LLN)。该声明未简单判定二者优劣,而是指出二者分别服务于不同的临床与流行病学目标,并强调当前更紧迫的问题在于肺量计应用不足、检查质量不稳定及结果脱离临床背景的机械性解读。本文系统梳理声明主要观点,重点介绍双方在肺量计临床应用障碍、固定比值与LLN差异、检查质量、预计值方程及严重程度分级等方面达成的共识,并结合我国临床实践、最新研究及技术进展提出建议,以期为我国慢阻肺病规范化诊断和筛查策略优化提供参考。.
引用
- Ji LL, Liang LN, Zheng JP, et al. [Interpretation of joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42706206. doi:10.3760/cma.j.cn112147-20260602-00330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。